116 related articles for article (PubMed ID: 11148564)
1. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.
Safra T; Groshen S; Jeffers S; Tsao-Wei DD; Zhou L; Muderspach L; Roman L; Morrow CP; Burnett A; Muggia FM
Cancer; 2001 Jan; 91(1):90-100. PubMed ID: 11148564
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
3. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer.
Wilailak S; Linasmita V
Oncology; 2004; 67(3-4):183-6. PubMed ID: 15557776
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
8. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
9. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract][Full Text] [Related]
13. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
16. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Hong RL; Tseng YL
Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]